JLP 1602Alternative Names: JLP-1602
Latest Information Update: 21 Mar 2016
At a glance
- Originator Jeil Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Diabetes mellitus
Most Recent Events
- 21 Mar 2016 Early research in Diabetes mellitus in South Korea (unspecified route) prior to March 2016 (Jeil Pharmaceutical's pipeline, March 2016)